Who
Lily Cheung
Chief Human Resource Officer
Company insider
Files Form 4 as: Chief Human Resource Officer, Pliant Therapeutics.
In numbers
- Trades disclosed
- 22
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $61K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 19 Jan 2023
- Last trade
- 17 Apr 2026
- Last filed
- 17 Apr 2026
Companies traded
Activity over time
1 Jan 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —123,000 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —123,000 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —52,000 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —123,000 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —123,000 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —52,000 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —52,000 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —51,750 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,750 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —52,000 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —51,750 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,750 at $0.00 | filing |
| 22 Jan 2026filed 26 Jan 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 22 Jan 2026filed 26 Jan 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 20 Jan 2026filed 22 Jan 2026 | PLRX Pliant TherapeuticsBiotechnology | SEC FORM 4 Sold | $9,6447,534 at $1.28 | filing |
| 20 Jan 2026filed 22 Jan 2026 | PLRX Pliant TherapeuticsBiotechnology | SEC FORM 4 Sold | $9,6447,534 at $1.28 | filing |
| 23 Jan 2025filed 27 Jan 2025 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,750 at $0.00 | filing |
| 23 Jan 2025filed 27 Jan 2025 | PLRX Pliant TherapeuticsBiotechnology | SEC FORM 4 Code A | —25,875 at $0.00 | filing |
| 17 Jan 2025filed 22 Jan 2025 | PLRX Pliant TherapeuticsBiotechnology | SEC FORM 4 Sold | $42K3,740 at $11.20 | filing |
| 23 Jan 2024filed 24 Jan 2024 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —52,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.